World-class medical cooling systems

– Reliable solutions with high-end support

BrainCool AB (publ) – last exercise period for BrainCool’s warrants, BRAIN TO 2, 2018-2021, September 17 – October 1, 2021


As part of our agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of September 17 – October 1, 2021, holders of BRAIN TO 2 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 2 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. Note that warrants in serie TO 2 that isn´t sold latest 29 September 2021 alternatively used 1 October is due without any value.

Holders of warrants who have their warrants nominee registered in the custody of a bank or broker shall contact their bank to exercise the warrants for subscription.

For directly registered warrant holders, subscription shall be made by filling in a completed application form and sending it to the issuing institution (Eminova Fondkommission) at the same time as payment is made.  The application form and payment must be made to Eminova no later than October 1, 2021, at 15:00. Application form can be ordered from Eminova on or 08-684 211 00.

Note that last day of trade with BRAIN TO 2 is 29 September.

-Series BRAIN TO 2 series warrants have ISIN code SE0011762418.

The terms and conditions of the warrants are published on BrainCool's website:

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.